Skip to main content
NCBI home page
Journal of Virology logoLink to Journal of Virology
. 1995 Jan;69(1):301–307. doi: 10.1128/jvi.69.1.301-307.1995

A mutant v-rel with increased ability to transform B lymphocytes.

P Romero 1, E H Humphries 1
PMCID: PMC188576  PMID: 7983722

Abstract

We observed that two strains of REV-T differ in the ability to transform bursal cells in vitro. REV-TW, with v-rel derived from a well-characterized clone and considered the prototype of the wild type, fails to generate colonies in soft agar. In contrast, REV-S2A3, derived from the S2A3 cell line, readily transforms bursal cells. With PCR, a 1,591-bp fragment containing v-rel from the REV-S2A3 provirus was cloned into plasmid pREV-0. Except for the absence of v-rel, pREV-0 is identical to pREV-TW. Five clones of pREV-PCR, each produced by an independent amplification, were obtained. The REV-PCR viruses displayed the strong transforming phenotype of REV-S2A3. Two mutations were identified in the 5' region of v-rel from REV-PCR1 to REV-PCR5: a silent mutation and a G-to-T transversion, changing the alanine at position 40 to serine. To confirm the relevance of this amino acid substitution, a 478-bp fragment containing the mutations was exchanged between REV-TW and REV-PCR1. Only the mutant viruses were able to form large colonies of bursal cells in liquid culture and to generate bursal cell colonies in soft agar. When tested on splenocytes, the wild-type viruses induced predominantly non-B-cell colonies while the mutant viruses gave origin mainly to B-cell colonies. The above results indicate that the substitution of serine for alanine at position 40 of v-Rel enhances the ability of REV-T to transform B lymphocytes in vitro. This mutation is close to the DNA-binding region, and the variant v-Rel oncoprotein shows increased kappa B-binding activity, thus confirming the relevance of this property for transformation.

Full Text

The Full Text of this article is available as a PDF (273.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abbadie C., Kabrun N., Bouali F., Smardova J., Stéhelin D., Vandenbunder B., Enrietto P. J. High levels of c-rel expression are associated with programmed cell death in the developing avian embryo and in bone marrow cells in vitro. Cell. 1993 Dec 3;75(5):899–912. doi: 10.1016/0092-8674(93)90534-w. [DOI] [PubMed] [Google Scholar]
  2. Baeuerle P. A., Baltimore D. I kappa B: a specific inhibitor of the NF-kappa B transcription factor. Science. 1988 Oct 28;242(4878):540–546. doi: 10.1126/science.3140380. [DOI] [PubMed] [Google Scholar]
  3. Baeuerle P. A. The inducible transcription activator NF-kappa B: regulation by distinct protein subunits. Biochim Biophys Acta. 1991 Apr 16;1072(1):63–80. doi: 10.1016/0304-419x(91)90007-8. [DOI] [PubMed] [Google Scholar]
  4. Ballard D. W., Walker W. H., Doerre S., Sista P., Molitor J. A., Dixon E. P., Peffer N. J., Hannink M., Greene W. C. The v-rel oncogene encodes a kappa B enhancer binding protein that inhibits NF-kappa B function. Cell. 1990 Nov 16;63(4):803–814. doi: 10.1016/0092-8674(90)90146-6. [DOI] [PubMed] [Google Scholar]
  5. Barth C. F., Ewert D. L., Olson W. C., Humphries E. H. Reticuloendotheliosis virus REV-T(REV-A)-induced neoplasia: development of tumors within the T-lymphoid and myeloid lineages. J Virol. 1990 Dec;64(12):6054–6062. doi: 10.1128/jvi.64.12.6054-6062.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Barth C. F., Humphries E. H. A nonimmunosuppressive helper virus allows high efficiency induction of B cell lymphomas by reticuloendotheliosis virus strain T. J Exp Med. 1988 Jan 1;167(1):89–108. doi: 10.1084/jem.167.1.89. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Barth C. F., Humphries E. H. Expression of v-rel induces mature B-cell lines that reflect the diversity of avian immunoglobulin heavy- and light-chain rearrangements. Mol Cell Biol. 1988 Dec;8(12):5358–5368. doi: 10.1128/mcb.8.12.5358. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Beug H., Müller H., Grieser S., Doederlein G., Graf T. Hematopoietic cells transformed in vitro by REVT avian reticuloendotheliosis virus express characteristics of very immature lymphoid cells. Virology. 1981 Dec;115(2):295–309. doi: 10.1016/0042-6822(81)90112-4. [DOI] [PubMed] [Google Scholar]
  9. Bhat G. V., Temin H. M. Mutational analysis of v-rel, the oncogene of reticuloendotheliosis virus strain T. Oncogene. 1990 May;5(5):625–634. [PubMed] [Google Scholar]
  10. Blank V., Kourilsky P., Israël A. NF-kappa B and related proteins: Rel/dorsal homologies meet ankyrin-like repeats. Trends Biochem Sci. 1992 Apr;17(4):135–140. doi: 10.1016/0968-0004(92)90321-y. [DOI] [PubMed] [Google Scholar]
  11. Boehmelt G., Walker A., Kabrun N., Mellitzer G., Beug H., Zenke M., Enrietto P. J. Hormone-regulated v-rel estrogen receptor fusion protein: reversible induction of cell transformation and cellular gene expression. EMBO J. 1992 Dec;11(12):4641–4652. doi: 10.1002/j.1460-2075.1992.tb05566.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Bose H. R., Jr The Rel family: models for transcriptional regulation and oncogenic transformation. Biochim Biophys Acta. 1992 Sep 14;1114(1):1–17. doi: 10.1016/0304-419x(92)90002-g. [DOI] [PubMed] [Google Scholar]
  13. Chen C. L., Ager L. L., Gartland G. L., Cooper M. D. Identification of a T3/T cell receptor complex in chickens. J Exp Med. 1986 Jul 1;164(1):375–380. doi: 10.1084/jem.164.1.375. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Chen I. S., Temin H. M. Substitution of 5' helper virus sequences into non-rel portion of reticuloendotheliosis virus strain T suppresses transformation of chicken spleen cells. Cell. 1982 Nov;31(1):111–120. doi: 10.1016/0092-8674(82)90410-x. [DOI] [PubMed] [Google Scholar]
  15. Cleary M. L. Oncogenic conversion of transcription factors by chromosomal translocations. Cell. 1991 Aug 23;66(4):619–622. doi: 10.1016/0092-8674(91)90105-8. [DOI] [PubMed] [Google Scholar]
  16. Diehl J. A., Hannink M. Heterologous C-terminal sequences disrupt transcriptional activation and oncogenesis by p59v-rel. J Virol. 1993 Dec;67(12):7161–7171. doi: 10.1128/jvi.67.12.7161-7171.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Diehl J. A., McKinsey T. A., Hannink M. Differential pp40I kappa B-beta inhibition of DNA binding by rel proteins. Mol Cell Biol. 1993 Mar;13(3):1769–1778. doi: 10.1128/mcb.13.3.1769. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Ghosh S., Gifford A. M., Riviere L. R., Tempst P., Nolan G. P., Baltimore D. Cloning of the p50 DNA binding subunit of NF-kappa B: homology to rel and dorsal. Cell. 1990 Sep 7;62(5):1019–1029. doi: 10.1016/0092-8674(90)90276-k. [DOI] [PubMed] [Google Scholar]
  19. Gilmore T. D. Malignant transformation by mutant Rel proteins. Trends Genet. 1991 Oct;7(10):318–322. doi: 10.1016/0168-9525(91)90421-l. [DOI] [PubMed] [Google Scholar]
  20. Gilmore T. D., Temin H. M. Different localization of the product of the v-rel oncogene in chicken fibroblasts and spleen cells correlates with transformation by REV-T. Cell. 1986 Mar 14;44(5):791–800. doi: 10.1016/0092-8674(86)90845-7. [DOI] [PubMed] [Google Scholar]
  21. Grilli M., Chiu J. J., Lenardo M. J. NF-kappa B and Rel: participants in a multiform transcriptional regulatory system. Int Rev Cytol. 1993;143:1–62. doi: 10.1016/s0074-7696(08)61873-2. [DOI] [PubMed] [Google Scholar]
  22. Gélinas C., Temin H. M. The v-rel oncogene encodes a cell-specific transcriptional activator of certain promoters. Oncogene. 1988 Oct;3(4):349–355. [PubMed] [Google Scholar]
  23. Hannink M., Temin H. M. Transactivation of gene expression by nuclear and cytoplasmic rel proteins. Mol Cell Biol. 1989 Oct;9(10):4323–4336. doi: 10.1128/mcb.9.10.4323. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Hoelzer J. D., Lewis R. B., Wasmuth C. R., Bose H. R., Jr Hematopoietic cell transformation by reticuloendotheliosis virus: characterization of the genetic defect. Virology. 1980 Jan 30;100(2):462–474. doi: 10.1016/0042-6822(80)90536-x. [DOI] [PubMed] [Google Scholar]
  25. Hrdlicková R., Nehyba J., Humphries E. H. v-rel induces expression of three avian immunoregulatory surface receptors more efficiently than c-rel. J Virol. 1994 Jan;68(1):308–319. doi: 10.1128/jvi.68.1.308-319.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Hunter T. Cooperation between oncogenes. Cell. 1991 Jan 25;64(2):249–270. doi: 10.1016/0092-8674(91)90637-e. [DOI] [PubMed] [Google Scholar]
  27. Inoue J., Kerr L. D., Ransone L. J., Bengal E., Hunter T., Verma I. M. c-rel activates but v-rel suppresses transcription from kappa B sites. Proc Natl Acad Sci U S A. 1991 May 1;88(9):3715–3719. doi: 10.1073/pnas.88.9.3715. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Kabrun N., Hodgson J. W., Doemer M., Mak G., Franza B. R., Jr, Enrietto P. J. Interaction of the v-rel protein with an NF-kappa B DNA binding site. Proc Natl Acad Sci U S A. 1991 Mar 1;88(5):1783–1787. doi: 10.1073/pnas.88.5.1783. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Kamens J., Richardson P., Mosialos G., Brent R., Gilmore T. Oncogenic transformation by vrel requires an amino-terminal activation domain. Mol Cell Biol. 1990 Jun;10(6):2840–2847. doi: 10.1128/mcb.10.6.2840. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Kemp B. E., Pearson R. B. Protein kinase recognition sequence motifs. Trends Biochem Sci. 1990 Sep;15(9):342–346. doi: 10.1016/0968-0004(90)90073-k. [DOI] [PubMed] [Google Scholar]
  31. Kerr L. D., Duckett C. S., Wamsley P., Zhang Q., Chiao P., Nabel G., McKeithan T. W., Baeuerle P. A., Verma I. M. The proto-oncogene bcl-3 encodes an I kappa B protein. Genes Dev. 1992 Dec;6(12A):2352–2363. doi: 10.1101/gad.6.12a.2352. [DOI] [PubMed] [Google Scholar]
  32. Kerr L. D., Inoue J., Davis N., Link E., Baeuerle P. A., Bose H. R., Jr, Verma I. M. The rel-associated pp40 protein prevents DNA binding of Rel and NF-kappa B: relationship with I kappa B beta and regulation by phosphorylation. Genes Dev. 1991 Aug;5(8):1464–1476. doi: 10.1101/gad.5.8.1464. [DOI] [PubMed] [Google Scholar]
  33. Kerr L. D., Ransone L. J., Wamsley P., Schmitt M. J., Boyer T. G., Zhou Q., Berk A. J., Verma I. M. Association between proto-oncoprotein Rel and TATA-binding protein mediates transcriptional activation by NF-kappa B. Nature. 1993 Sep 30;365(6445):412–419. doi: 10.1038/365412a0. [DOI] [PubMed] [Google Scholar]
  34. Kieran M., Blank V., Logeat F., Vandekerckhove J., Lottspeich F., Le Bail O., Urban M. B., Kourilsky P., Baeuerle P. A., Israël A. The DNA binding subunit of NF-kappa B is identical to factor KBF1 and homologous to the rel oncogene product. Cell. 1990 Sep 7;62(5):1007–1018. doi: 10.1016/0092-8674(90)90275-j. [DOI] [PubMed] [Google Scholar]
  35. Kochel T., Rice N. R. v-rel- and c-rel-protein complexes bind to the NF-kappa B site in vitro. Oncogene. 1992 Mar;7(3):567–572. [PubMed] [Google Scholar]
  36. Kumar S., Rabson A. B., Gélinas C. The RxxRxRxxC motif conserved in all Rel/kappa B proteins is essential for the DNA-binding activity and redox regulation of the v-Rel oncoprotein. Mol Cell Biol. 1992 Jul;12(7):3094–3106. doi: 10.1128/mcb.12.7.3094. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Lewis R. B., McClure J., Rup B., Niesel D. W., Garry R. F., Hoelzer J. D., Nazerian K., Bose H. R., Jr Avian reticuloendotheliosis virus: identification of the hematopoietic target cell for transformation. Cell. 1981 Aug;25(2):421–431. doi: 10.1016/0092-8674(81)90060-x. [DOI] [PubMed] [Google Scholar]
  38. Liou H. C., Baltimore D. Regulation of the NF-kappa B/rel transcription factor and I kappa B inhibitor system. Curr Opin Cell Biol. 1993 Jun;5(3):477–487. doi: 10.1016/0955-0674(93)90014-h. [DOI] [PubMed] [Google Scholar]
  39. Lu D., Thompson J. D., Gorski G. K., Rice N. R., Mayer M. G., Yunis J. J. Alterations at the rel locus in human lymphoma. Oncogene. 1991 Jul;6(7):1235–1241. [PubMed] [Google Scholar]
  40. Matthews J. R., Kaszubska W., Turcatti G., Wells T. N., Hay R. T. Role of cysteine62 in DNA recognition by the P50 subunit of NF-kappa B. Nucleic Acids Res. 1993 Apr 25;21(8):1727–1734. doi: 10.1093/nar/21.8.1727. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. McDonnell P. C., Kumar S., Rabson A. B., Gélinas C. Transcriptional activity of rel family proteins. Oncogene. 1992 Jan;7(1):163–170. [PubMed] [Google Scholar]
  42. Moore B. E., Bose H. R., Jr Expression of the v-rel oncogene in reticuloendotheliosis virus-transformed fibroblasts. Virology. 1988 Feb;162(2):377–387. doi: 10.1016/0042-6822(88)90478-3. [DOI] [PubMed] [Google Scholar]
  43. Morrison L. E., Boehmelt G., Enrietto P. J. Mutations in the rel-homology domain alter the biochemical properties of v-rel and render it transformation defective in chicken embryo fibroblasts. Oncogene. 1992 Jun;7(6):1137–1147. [PubMed] [Google Scholar]
  44. Mosialos G., Hamer P., Capobianco A. J., Laursen R. A., Gilmore T. D. A protein kinase-A recognition sequence is structurally linked to transformation by p59v-rel and cytoplasmic retention of p68c-rel. Mol Cell Biol. 1991 Dec;11(12):5867–5877. doi: 10.1128/mcb.11.12.5867. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Nehyba J., Hrdlicková R., Humphries E. H. Evolution of the oncogenic potential of v-rel: rel-induced expression of immunoregulatory receptors correlates with tumor development and in vitro transformation. J Virol. 1994 Apr;68(4):2039–2050. doi: 10.1128/jvi.68.4.2039-2050.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Neri A., Chang C. C., Lombardi L., Salina M., Corradini P., Maiolo A. T., Chaganti R. S., Dalla-Favera R. B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-kappa B p50. Cell. 1991 Dec 20;67(6):1075–1087. doi: 10.1016/0092-8674(91)90285-7. [DOI] [PubMed] [Google Scholar]
  47. Nichols J., Nimer S. D. Transcription factors, translocations, and leukemia. Blood. 1992 Dec 15;80(12):2953–2963. [PubMed] [Google Scholar]
  48. Nolan G. P., Ghosh S., Liou H. C., Tempst P., Baltimore D. DNA binding and I kappa B inhibition of the cloned p65 subunit of NF-kappa B, a rel-related polypeptide. Cell. 1991 Mar 8;64(5):961–969. doi: 10.1016/0092-8674(91)90320-x. [DOI] [PubMed] [Google Scholar]
  49. Ohno H., Takimoto G., McKeithan T. W. The candidate proto-oncogene bcl-3 is related to genes implicated in cell lineage determination and cell cycle control. Cell. 1990 Mar 23;60(6):991–997. doi: 10.1016/0092-8674(90)90347-h. [DOI] [PubMed] [Google Scholar]
  50. Perkins N. D., Schmid R. M., Duckett C. S., Leung K., Rice N. R., Nabel G. J. Distinct combinations of NF-kappa B subunits determine the specificity of transcriptional activation. Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1529–1533. doi: 10.1073/pnas.89.5.1529. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Richardson P. M., Gilmore T. D. vRel is an inactive member of the Rel family of transcriptional activating proteins. J Virol. 1991 Jun;65(6):3122–3130. doi: 10.1128/jvi.65.6.3122-3130.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Ryseck R. P., Bull P., Takamiya M., Bours V., Siebenlist U., Dobrzanski P., Bravo R. RelB, a new Rel family transcription activator that can interact with p50-NF-kappa B. Mol Cell Biol. 1992 Feb;12(2):674–684. doi: 10.1128/mcb.12.2.674. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Sarkar S., Gilmore T. D. Transformation by the vRel oncoprotein requires sequences carboxy-terminal to the Rel homology domain. Oncogene. 1993 Aug;8(8):2245–2252. [PubMed] [Google Scholar]
  54. Schwartz R. C., Witte O. N. A recombinant murine retrovirus expressing v-rel is cytopathic. Virology. 1988 Jul;165(1):182–190. doi: 10.1016/0042-6822(88)90671-x. [DOI] [PubMed] [Google Scholar]
  55. Stephens R. M., Rice N. R., Hiebsch R. R., Bose H. R., Jr, Gilden R. V. Nucleotide sequence of v-rel: the oncogene of reticuloendotheliosis virus. Proc Natl Acad Sci U S A. 1983 Oct;80(20):6229–6233. doi: 10.1073/pnas.80.20.6229. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Stoker A. W., Bissell M. J. Quantitative immunocytochemical assay for infectious avian retroviruses. J Gen Virol. 1987 Sep;68(Pt 9):2481–2485. doi: 10.1099/0022-1317-68-9-2481. [DOI] [PubMed] [Google Scholar]
  57. Sylla B. S., Temin H. M. Activation of oncogenicity of the c-rel proto-oncogene. Mol Cell Biol. 1986 Dec;6(12):4709–4716. doi: 10.1128/mcb.6.12.4709. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Walker W. H., Stein B., Ganchi P. A., Hoffman J. A., Kaufman P. A., Ballard D. W., Hannink M., Greene W. C. The v-rel oncogene: insights into the mechanism of transcriptional activation, repression, and transformation. J Virol. 1992 Aug;66(8):5018–5029. doi: 10.1128/jvi.66.8.5018-5029.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. White D. W., Gilmore T. D. Temperature-sensitive transforming mutants of the v-rel oncogene. J Virol. 1993 Nov;67(11):6876–6881. doi: 10.1128/jvi.67.11.6876-6881.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Wilhelmsen K. C., Eggleton K., Temin H. M. Nucleic acid sequences of the oncogene v-rel in reticuloendotheliosis virus strain T and its cellular homolog, the proto-oncogene c-rel. J Virol. 1984 Oct;52(1):172–182. doi: 10.1128/jvi.52.1.172-182.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Wulczyn F. G., Naumann M., Scheidereit C. Candidate proto-oncogene bcl-3 encodes a subunit-specific inhibitor of transcription factor NF-kappa B. Nature. 1992 Aug 13;358(6387):597–599. doi: 10.1038/358597a0. [DOI] [PubMed] [Google Scholar]
  62. Zhang J. Y., Bargmann W., Bose H. R., Jr Rearrangement and diversification of immunoglobulin light-chain genes in lymphoid cells transformed by reticuloendotheliosis virus. Mol Cell Biol. 1989 Nov;9(11):4970–4976. doi: 10.1128/mcb.9.11.4970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Zhang J. Y., Olson W., Ewert D., Bargmann W., Bose H. R., Jr The v-rel oncogene of avian reticuloendotheliosis virus transforms immature and mature lymphoid cells of the B cell lineage in vitro. Virology. 1991 Aug;183(2):457–466. doi: 10.1016/0042-6822(91)90975-h. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES